Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 21, 2021; 27(31): 5181-5188
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5181
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5181
Table 3 Clinical outcomes of hepatitis C virus-related hepatitis flare during chemotherapy
| Ref. | Study type | Cancer type | Liver decompensation | Interruption of chemotherapy | Mortality due to HCV reactivation |
| Torres et al[18] | Prospective observation study | Hematological tumor (n = 18) | Total: 0% | Total: 26% | Total: 0% |
| Solid tumor (n = 5) | |||||
| Fujii et al[6] | Prospective study | Leukemia (n = 21) | Total: 28.6% | — | — |
| Li et al[4] | Retrospective observation study | Hematological tumor (n = 3) | Total: 0% | Total: 57% | Total: 0% |
| (Hematological tumor: 0%; | (Hematological tumor: 67%; | (Hematological tumor: 0%; | |||
| HCC (n = 2) | HCC: 0%; | HCC: 50%; | HCC: 0%; | ||
| Non-HCC solid tumor (n = 2) | Non-HCC solid tumor: 0%) | solid tumor: 50%) | Non-HCC solid tumor: 0%) | ||
| Lee et al[16] | Retrospective study | Hematological tumor (n = 14) | Total: 0% | Total: 32% | Total: 0% |
| Solid tumor (n = 11) | |||||
| Mahale et al[5] | Retrospective study | Hematological tumor (n = 24) | Total: 0% | Total: 45% | Total: 0% |
| Solid tumor (n = 9) | |||||
| Zuckerman et al[7] | Retrospective study | Hematological tumor (n = 33) | Total: 0% | — | Total: 0% |
- Citation: Li YR, Hu TH, Chen WC, Hsu PI, Chen HC. Screening and prevention of hepatitis C virus reactivation during chemotherapy. World J Gastroenterol 2021; 27(31): 5181-5188
- URL: https://www.wjgnet.com/1007-9327/full/v27/i31/5181.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i31.5181